newsAn RNAi therapeutic that has best-in-disease potential for hypertension is…
24 July 2023 | By Catherine Eckford (European Pharmaceutical Review)
An RNAi therapeutic that has best-in-disease potential for hypertension is set to be developed under a partnership between Roche and Alnylam Pharmaceuticals.